INTS INTENSITY THERAPEUTICS, INC.

Nasdaq intensitytherapeutics.com


$ 0.28 $ 0.02 (6.78 %)    

Monday, 20-Oct-2025 16:58:05 EDT
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 0.2786
$ 0.26
$ 0.25 x 100
$ 0.30 x 5,250
$ 0.26 - $ 0.29
$ 0.19 - $ 3.44
2,752,029
na
13.11M
$ -0.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 intensity-therapeutics-reports-early-radiological-and-pathological-results-with-int230-6-demonstrating-high-drug-absorption-tumor-necrosis-and-evidence-of-immune-activation

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patie...

 benchmark-maintains-speculative-buy-on-intensity-therapeutics-lowers-price-target-to-15

Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the pric...

 brookline-capital-upgrades-intensity-therapeutics-to-buy-announces-3-price-target

Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 pr...

 intensity-therapeutics-regains-nasdaq-compliance

Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology ...

 intensity-therapeutics-q2-eps-013-beats-020-estimate

Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate o...

 intensity-therapeutics-raises-66m-through-stock-sales-of-19m-shares-at-03323share-to-fund-cancer-trials

 Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology...

 us-stocks-likely-to-open-lower-look-through-near-term-noise-be-deliberate-about-the-kinds-of-risk-youre-taking-leverage-ai-say-experts

U.S. stock futures were trading lower on Thursday after closing lower on Wednesday. Futures of major benchmark indices declined...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION